Santhera Pharmaceuticals submits NDA in South Korea for Raxone for the treatment of LHON
Santhera Pharmaceuticals said on Tuesday that the Korean Ministry of Food and Drug Safety (MFDS) has accepted its new drug…
Pharmaceuticals, Biotechnology and Life Sciences
Santhera Pharmaceuticals said on Tuesday that the Korean Ministry of Food and Drug Safety (MFDS) has accepted its new drug…
Announcing the phase 2 testing on Monday, the company said that the multicenter study of EC-18 (Mosedipimod), the world’s first oral medicine candidate to prevent and treat Chemotherapy-Induced Neutropenia (CIN), will begin dosing its first patient in the Asan Medical Center of Seoul, Korea. Enzychem also said it hopes to have EC-18 be approved by the FDA.
South Korea said on Thursday it has fined Swiss drugmaker Novartis 55.1 billion won ($48.80 million) for offering doctors kickbacks to recommend the company’s drugs, and also suspended insurance coverage for some of its drugs.